4 August 2022
Arecor Therapeutics plc
("Arecor" or the "Company" or the "Group")
Director/PDMR Dealings
and
Completion of the Acquisition of Tetris Pharma
Arecor Therapeutics plc (AIM: AREC), a globally focused biopharmaceutical company advancing today's therapies to enable healthier lives, announces that further to the Placing and acquisition of Tetris Pharma, details of which were announced on 1 August 2022, pursuant to the Placing, the following Directors subscribed for an aggregate amount of £113,271 at the Placing Price of 300 pence per ordinary share.
Following General Admission today, the Placing and acquisition of Tetris Pharma have now completed.
The following Directors interests in Ordinary Shares are as follows:
|
Name |
Placing Shares acquired |
Resultant shareholding following Admission |
% of the Enlarged Share Capital |
|
Sarah Howell (Chief Executive Officer) |
6,666 |
847,072.00 |
2.8% |
|
Susan Lowther (Chief Financial Officer) |
3,334 |
139,849.00 |
0.5% |
|
Andrew Richards (Chair) |
6,666 |
223,834.00 |
0.7% |
|
Sam Fazeli (Non-Executive Director) |
7,756 |
115,708.00 |
0.4% |
|
Jeremy Morgan (Non-Executive Director) |
6,666 |
27,169.00 |
0.1% |
|
Christine Soden (Non-Executive Director) |
6,667 |
19,167.00 |
0.1% |
|
Total |
37,755 |
|
|
The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.00 a.m. on 1 August 2022 unless otherwise stated.
For more information, please contact:
|
Arecor Therapeutics plc |
|
|
Dr Sarah Howell, Chief Executive Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Susan Lowther, Chief Financial Officer |
Tel: +44 (0) 1223 426060 Email: info@arecor.com |
|
|
|
|
Mo Noonan, Communications |
Tel: +44 (0) 7876 444977 Email: mo.noonan@arecor.com |
|
|
|
|
Panmure Gordon (UK) Limited (NOMAD and Broker) |
|
|
Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) |
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
Consilium Strategic Communications |
|
|
Chris Gardner, David Daley, Angela Gray |
Tel: +44 (0) 20 3709 5700 Email: arecor@consilium-comms.com |
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
a) Sarah Howell b) Susan Lowther c) Andrew Richards d) Sam Fazeli e) Jeremy Morgan f) Christine Soden
|
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
a) Chief Executive Officer b) Chief Financial Officer c) Chair d) Non-executive Director e) Non-executive Director f) Non-executive Director
|
|||
|
b)
|
Initial notification /Amendment
|
Initial Notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
Arecor Therapeutics plc |
|||
|
b)
|
LEI
|
98450093D12I3A8DDD58 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary Shares of 1p each |
|||
|
|
|
||||
|
Identification code |
ISIN: GB00BMWLM973 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Purchase of Ordinary Shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
a) 300 pence b) 300 pence c) 300 pence d) 300 pence e) 300 pence f) 300 pence |
a) 6,666 b) 3,334 c) 6,666 d) 7,756 e) 6,666 f) 6,667 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
|
|||
|
|
|
||||
|
- Aggregated volume |
37,755 |
||||
|
|
|
||||
|
- Price |
300 pence |
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
4 August 2022 |
|||
|
f)
|
Place of the transaction
|
XLON |
|||
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical group transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
